IDL Diagnostics AB (publ) (80R)

Overview

AroCell AB (publ) is a pioneering company in the field of in vitro diagnostics, focusing on the development and commercialization of blood and urine sample testing products intended for the treatment of various cancers, including breast, prostate, and bladder cancers. Initially founded in 2000 as Xi Bao Research AB, the company underwent a rebranding to AroCell AB (publ) in 2006. With its headquarters located in Stockholm, Sweden, AroCell stands out in the diagnostics industry by offering innovative and reliable solutions for the monitoring and diagnosis of cancer.

Products and Services

AroCell TK 210 ELISA: This immunoassay kit is designed for the quantification of human Thymidine Kinase 1 protein levels in blood samples. Thymidine Kinase 1 is a biomarker that can be indicative of active cellular division, making it a valuable tool for assessing tumor aggressiveness and monitoring the effectiveness of cancer treatment regimes.

UBC Rapid: A product tailored for the diagnosis and follow-up care of bladder cancer patients. UBC Rapid offers a non-invasive testing solution, analyzing urine samples for the presence of specific biomarkers associated with bladder cancer. This test represents a significant advancement in the management and treatment of bladder cancer, providing prompt and reliable results.

TUBEX TF: This diagnostic tool is employed for the detection of acute typhoid fever. Utilizing an in vitro diagnostic test, TUBEX TF enables healthcare professionals to quickly diagnose typhoid fever, thereby facilitating immediate and appropriate treatment responses. This product underscores AroCell's commitment to extending its diagnostic expertise beyond oncology, addressing infectious diseases as well.